The Lynx Group
Cholangiocarcinoma News

Phase 2 Study of Nivolumab with Gemcitabine/Cisplatin or Ipilimumab as First-Line Therapy for Patients with Advanced Unresectable BTC (BilT-01)

Web Exclusives — May 30, 2020

This randomized, phase 2 multi-institutional study was designed to investigate the role of combinational immunotherapy, using nivolumab with gemcitabine/cisplatin, or nivolumab with ipilimumab in patients with untreated advanced biliary tract cancer.1

Arm A included gemcitabine 1000 mg/m2 and cisplatin 25 mg/m2 on days 1 and 8 every 3 weeks plus nivolumab 360 mg on day 1 every 3 weeks for 6 months followed by nivolumab 240 mg every 2 weeks as monotherapy for a total duration of 2 years; arm B included nivolumab 240 mg every 2 weeks and ipilimumab 1 mg/kg every 6 weeks for 2 years, in the absence of disease progression. The primary end point was progression-free survival (PFS) at 6 months. Secondary end points included best overall response rate per immune-related RECIST, median PFS, overall survival, and safety. Exploratory objectives included biomarker analysis using sequential whole exome/transcriptome and immune cell subsets in tissue and blood.

A total of 64 eligible patients were enrolled: 32 in arm A and 32 in arm B, with a median age of 62 years (range, 20-80 years), and 90% with metastatic disease. PFS at 6 months was 64.2% in arm A and 23.4% in arm B. Median PFS was 7.4 months in arm A and 4.1 months in arm B. Median overall survival was 10.6 in arm A and 8.3 in arm B. Whereas PFS in arm B was inferior to historical controls, arm A appeared to be as effective as standard-of-care chemotherapy. A total of 40% of patients in arm A are still alive, which suggests that there may be a “tail” on the survival curve. Analyses are still pending for safety and toxicity, overall response rate, genomic analysis, and immune subset analysis.

Although arm A was not superior to standard-of-care chemotherapy, there are 2 phase 3 trials currently open globally that are accruing patients (NCT04003636 and NCT03875235). ClinicalTrials.gov number NCT03101566.

Reference

  1. Sahai V, et al. ASCO 2020. Abstract 4582.

Subscribe to CCA News

Stay up to date with personalized medicine by subscribing to recieve the free CCA News print publication or weekly e‑Newsletter.

I'd like to recieve: